Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG-OCT: OCT1 Polymorphisms and Pharmacokinetics
NCT02054299Phase 1Completed
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Apr 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of amitriptyline, desvenlafaxine, sumatriptan, proguanil, fenoterol and 1 more in major depressive disorder (MDD), migraine, malaria and 2 more, sponsored by Universitätsmedizin Göttingen. Primary endpoint: Area under the plasma concentration-time curve up to 60 hours. Started Apr 2013; status: completed.
02
Drugs
amitriptylinedesvenlafaxinesumatriptanproguanilfenoterol
03
Conditions
major depressive disorder (MDD)migrainemalariaasthmathiamine deficiency
Beyond the preview
Go deeper on NCT02054299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054299.